Abstract
You have accessJournal of UrologyBenign Prostatic Hyperplasia: Surgical Therapy & New Technology III1 Apr 2017PD23-06 THULIUM VAPOENUCLEATION OF THE PROSTATE VERSUS HOLMIUM LASER ENUCLEATION OF THE PROSTATE: 6-MONTH SAFETY AND EFFICACY RESULTS OF A PROSPECTIVE RANDOMIZED TRIAL Christopher Netsch, Benedikt Becker, Christian Tiburtius, Christina Moritz, Arcangelo Venneri Becci, Thomas Herrmann, and Andreas Gross Christopher NetschChristopher Netsch More articles by this author , Benedikt BeckerBenedikt Becker More articles by this author , Christian TiburtiusChristian Tiburtius More articles by this author , Christina MoritzChristina Moritz More articles by this author , Arcangelo Venneri BecciArcangelo Venneri Becci More articles by this author , Thomas HerrmannThomas Herrmann More articles by this author , and Andreas GrossAndreas Gross More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2017.02.1070AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES To compare the 6-month outcomes of thulium vapoenucleation of the prostate (ThuVEP) with holmium laser enucleation of the prostate (HoLEP) for patients with symptomatic benign prostatic obstruction (BPO). METHODS A prospective randomized trial comparing ThuVEP with HoLEP was conducted from February 2015 to February 2016 at the Asklepios Klinik Barmbek. A total of 94 patients with symptomatic BPO were prospectively randomized to ThuVEP (n=48) or HoLEP (n=46). All patients were assessed preoperatively by International Prostate Symptom Score (IPSS), Quality of Life (QoL), maximum urinary flow rate (Qmax), post-void residual urine (PVR), PSA, and prostate volume measurement by transrectal ultrasound. The patients were reassessed with the same tests at 1-month and 6-month follow-up. The complications were noted and classified according to the modified Clavien classification system. Patient data were expressed as median (interquartile range) or numbers (%). RESULTS There were no statistically significant differences in any baseline characteristics between the groups. Median age at surgery was 73 (67-76) yrs. and median prostate volume was 80 (46.75-100) cc. 43 (45.7%) patients presented in urinary retention with an indwelling catheter. The median operative time was 60 (41-79) minutes without significant differences between the groups. There were no significant differences between the groups regarding catheter time (2 (2-2) days) and postoperative stay (2 (2-3) days). Clavien 1 (13.8%), 2 (3.2%), 3a (2.1%), and Clavien 3b (4.3%) complications occurred without significant differences between the groups. However, the occurrence of acute postoperative urinary retention was significantly higher after HoLEP compared to ThuVEP (15.2% vs. 2.1%, p≤0.022) at 4-week follow-up. At 6-month follow-up, median Qmax (10.7 vs. 25.9 ml/s), PVR (100 vs. 6.5 ml), IPSS (20 vs. 5), QoL (4 vs. 1), PSA (4.14 vs. 0.71 μg/l), and prostate volume (80 vs. 16 ml) had improved significantly (p<0.001) compared to baseline without differences between the groups. The median PSA decrease was 79.7% (58.8-90.6%) and the median prostate volume reduction was 74.5% (68.57-87.63%) without differences between the groups. The reoperation rate was zero at 6-month follow-up. CONCLUSIONS ThuVEP and HoLEP are both safe and effective procedures for the treatment of symptomatic BPO. Both procedures give equivalent and satisfactory micturition improvement with low morbidity and sufficient prostate volume reduction at 6-month follow-up. © 2017FiguresReferencesRelatedDetails Volume 197Issue 4SApril 2017Page: e449 Advertisement Copyright & Permissions© 2017MetricsAuthor Information Christopher Netsch More articles by this author Benedikt Becker More articles by this author Christian Tiburtius More articles by this author Christina Moritz More articles by this author Arcangelo Venneri Becci More articles by this author Thomas Herrmann More articles by this author Andreas Gross More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.